BDRX — Biodexa Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $0.02m
- -$1.23m
- 18
- 60
- 17
- 22
Annual cashflow statement for Biodexa Pharmaceuticals, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -22.2 | -5.46 | -7.66 | -7.08 | -5.73 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 11.3 | -1.49 | -0.933 | -0.826 | -3.18 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.396 | 0.54 | 1.2 | 0.796 | -3.61 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -9.3 | -6.01 | -7.05 | -6.83 | -12.3 |
| Capital Expenditures | -0.209 | -0.32 | -0.062 | -0.263 | -0.774 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 2.78 | 0.042 | -0.158 | -0.002 | 0.176 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 2.57 | -0.278 | -0.22 | -0.265 | -0.598 |
| Financing Cash Flow Items | 0.011 | -0.015 | -0.018 | -0.013 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 3.08 | 8.8 | 0.047 | 10.2 | 8.56 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -3.38 | 2.51 | -7.22 | 3.13 | -4.3 |